Sanger sequencing from the corresponding patients’ tumor DNA failed to confirm any of the 2 variants in BRCA2 as well as the c.3352C>T variant in BRCA1. Therefore, we concluded that NGS gave rise to 3 false-positive mutations in this cohort. The gene discussed is BRCA2; the disease is neoplasm.